SNDX Martin H Huber JR. buys $45K worth of shares
May 20, 2025, 4:36 AM
0.00%
What does SNDX do
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Martin H Huber JR. bought 5,000 shares of SNDX on 19 May at $8.99 per share, worth a total of $45K. They now own 79,000 SNDX shares, or a 7% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.